Vanguard Global Advisers’s CorMedix CRMD Stock Holding History

Vanguard Global Advisers’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$218K	Hold	27,718	–	–	﹤0.01%	2466
2026 Q1	$188K	Buy	+27,718	New	+$205K	﹤0.01%	2471

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Global Advisers's CRMD Position: Q2 2026 in Review

Vanguard Global Advisers held its CorMedix (CRMD) position steady in Q2 2026 at 27,718 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #2466.

Vanguard Global Advisers first reported a position in CRMD in Q1 2026 and has held it in 2 quarters since. 188 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Vanguard Global Advisers held 27,718 shares of CorMedix worth $218K as of Q2 2026.
Vanguard Global Advisers left its CorMedix share count unchanged in Q2 2026.
CorMedix made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2466 holding.
Vanguard Global Advisers first reported a position in CorMedix in Q1 2026 and has held it in 2 quarters since.
188 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.